Section Arrow
Quote
NVCR.NASDAQ
- NovoCure Limited
Quotes are at least 15-min delayed:2026/03/29 20:18 EDT
Regular Hours
Last
 10.97
-0.79 (-6.72%)
Day High 
11.62 
Prev. Close
11.76 
1-M High
14.3794 
Volume 
1.21M 
Bid
10.97
Ask
11.02
Day Low
10.935 
Open
11.62 
1-M Low
11.2378 
Market Cap 
1.32B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 11.94 
20-SMA 12.54 
50-SMA 12.34 
52-W High 20.06 
52-W Low 9.82 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.22/-0.62
Enterprise Value
1.55B
Balance Sheet
Book Value Per Share
2.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
655.35M
Operating Revenue Per Share
4.50
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BSXBoston Scientific Corp69.17-1-1.43%36.18PE
ABTAbbott Laboratories103.99-0.58-0.55%28.17PE
MDTMedtronic plc87.14+0.18+0.21%24.57PE
PACBPacific Biosciences of California1.26-0.09-6.67%-- 
VNRXVolitionRX Limited0.1966+0.0036+1.87%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.